We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemours (CC) Starts Opteon 1150 Production in its New Plant
Read MoreHide Full Article
The Chemours Company (CC - Free Report) recently earmarked a new facility for the expansion of its non-ozone depleting, low global warming potential (GWP), hydrofluoroolefin (HFO) platform, Opteon 1150, which is chemically known as HFO-1336mzzE. The plant, located in El Dorado, AR, will open before the initial 10% phase down of CO2 equivalents scheduled before Jan 1, 2022, per the American Innovation and Manufacturing Act in the United States.
Opteon 1150 is an addition to the Chemours portfolio of non-flammable foam blowing agents, besides Opteon 1100. This is the latest innovation by Chemours and is testimony to its commitment to providing sustainable and energy-efficient products globally.
With the unique properties of HFO-1336mzzE, Opteon 1150 promises to mitigate some of the most difficult challenges in its industry through sustainable solutions, as well as to provide higher yields and a broader application window.
The company noted that the technology will be critical across multiple industries in transitioning to low GWP technology while maintaining the established high-performance standards. The product will bring more options and more control of formulations to Chemours’ customers. The company has already started accepting orders for Opteon 1150.
Chemours shares have grown 49.4% over the past year compared with the industry’s 28.8% rise. The company’s estimated earnings growth rate for the current year is pegged at 105.1%.
Image Source: Zacks Investment Research
Chemours, in its third-quarter call, raised expectations for full-year 2021 on the back of its strong third-quarter performance. It now sees adjusted EBITDA within the range of $1,300-$1,340 million compared with the prior guidance in the top end of the $1,100-$1,250 million range.
The company also expects adjusted earnings per share in the band of $3.93-$4.13 compared with the prior guidance in the top end of the $2.84-$3.56 range.
Free cash flow for 2021 is now forecast to be more than $500 million, up from prior guidance of above $450 million.
Dow has an expected earnings growth rate of 447% for the current year. The Zacks Consensus Estimate for earnings for the current year has been revised 8.7% upward over the last 60 days.
Dow beat the Zacks Consensus Estimate for earnings in all the four trailing quarters. The company pulled off a trailing four-quarter earnings surprise of roughly 14.12%, on average. Its shares have also gained around 12.6% over a year.
Univar has an expected earnings growth rate of 55.2% for the current year. The Zacks Consensus Estimate for the current year has been revised around 9% upward over the last 60 days.
Univar beat the Zacks Consensus Estimate for earnings in all of the four trailing quarters. The company delivered a trailing four-quarter earnings surprise of roughly 24.1%, on average. Its shares have also rallied around 68.2% over a year.
Celanese has an expected earnings growth rate of 139.7% for the current year. The Zacks Consensus Estimate for the current year has been revised 9.1% upward over the last 60 days.
Celanese beat the Zacks Consensus Estimate for earnings in all of the four trailing quarters. The company pulled off a trailing four-quarter earnings surprise of roughly 12.7%, on average. Its shares have also rallied around 37% over a year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Chemours (CC) Starts Opteon 1150 Production in its New Plant
The Chemours Company (CC - Free Report) recently earmarked a new facility for the expansion of its non-ozone depleting, low global warming potential (GWP), hydrofluoroolefin (HFO) platform, Opteon 1150, which is chemically known as HFO-1336mzzE. The plant, located in El Dorado, AR, will open before the initial 10% phase down of CO2 equivalents scheduled before Jan 1, 2022, per the American Innovation and Manufacturing Act in the United States.
Opteon 1150 is an addition to the Chemours portfolio of non-flammable foam blowing agents, besides Opteon 1100. This is the latest innovation by Chemours and is testimony to its commitment to providing sustainable and energy-efficient products globally.
With the unique properties of HFO-1336mzzE, Opteon 1150 promises to mitigate some of the most difficult challenges in its industry through sustainable solutions, as well as to provide higher yields and a broader application window.
The company noted that the technology will be critical across multiple industries in transitioning to low GWP technology while maintaining the established high-performance standards. The product will bring more options and more control of formulations to Chemours’ customers. The company has already started accepting orders for Opteon 1150.
Chemours shares have grown 49.4% over the past year compared with the industry’s 28.8% rise. The company’s estimated earnings growth rate for the current year is pegged at 105.1%.
Chemours, in its third-quarter call, raised expectations for full-year 2021 on the back of its strong third-quarter performance. It now sees adjusted EBITDA within the range of $1,300-$1,340 million compared with the prior guidance in the top end of the $1,100-$1,250 million range.
The company also expects adjusted earnings per share in the band of $3.93-$4.13 compared with the prior guidance in the top end of the $2.84-$3.56 range.
Free cash flow for 2021 is now forecast to be more than $500 million, up from prior guidance of above $450 million.
The Chemours Company Price and Consensus
The Chemours Company price-consensus-chart | The Chemours Company Quote
Zacks Rank & Other Key Picks
Chemours currently carries a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks in the basic materials space are Dow Inc. (DOW - Free Report) , Univar Solutions Inc. , each flaunting a Zacks Rank #1, and Celanese Corporation (CE - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Dow has an expected earnings growth rate of 447% for the current year. The Zacks Consensus Estimate for earnings for the current year has been revised 8.7% upward over the last 60 days.
Dow beat the Zacks Consensus Estimate for earnings in all the four trailing quarters. The company pulled off a trailing four-quarter earnings surprise of roughly 14.12%, on average. Its shares have also gained around 12.6% over a year.
Univar has an expected earnings growth rate of 55.2% for the current year. The Zacks Consensus Estimate for the current year has been revised around 9% upward over the last 60 days.
Univar beat the Zacks Consensus Estimate for earnings in all of the four trailing quarters. The company delivered a trailing four-quarter earnings surprise of roughly 24.1%, on average. Its shares have also rallied around 68.2% over a year.
Celanese has an expected earnings growth rate of 139.7% for the current year. The Zacks Consensus Estimate for the current year has been revised 9.1% upward over the last 60 days.
Celanese beat the Zacks Consensus Estimate for earnings in all of the four trailing quarters. The company pulled off a trailing four-quarter earnings surprise of roughly 12.7%, on average. Its shares have also rallied around 37% over a year.